Infinity Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to discovering, developing and delivering medicines to people with difficult-to-treat diseases. The Company develops small molecule drugs that target emerging disease pathways. The Company has worldwide development and commercialization rights to all of its development candidates and early discovery programs, subject to certain financial obligations to its current licensor and former development partners. The Company operates in one business segment, which focuses on drug discovery and development. IPI-145, the Company’s lead product candidate, is a potent, oral inhibitor of Class I delta and gamma isoforms of phosphoinositide-3-kinase, or PI3K, which the Company is investigating in both hematologic malignancies and inflammatory diseases. The PI3Ks are a family of enzymes involved in multiple cellular functions, including cell proliferation and survival, cell differentiation, cell migration and immunity.